An observational study in Post-partum Depression, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior.
Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.
Patients will be recruited by the physician in charge of the study or collaborators of the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution. In the study, exposure to citalopram treatment will be 12 weeks with follow-up every 4 weeks. At each participant, at the time of enrollment, will be assigned a unique code so that only the local investigators can trace the subject's identity. As part of a scheduled visit to assess the clinical diagnosis, the PPD patient will be offered to participate in the study, after the appropriate signing of informed consent, the verification of absence of criteria for exclusion and existence of the study inclusion criteria. If these criteria are met, some demographic and clinical medical history of the women with PPD will be collected, as already provided by clinical practice for the management of the disease. Patients will undergo MRI scanning at baseline at the S.C. Neuroradiology of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and will begin the pharmacological treatment with citalopram. It is emphasized that the administration of citalopram therapy for the treatment of depressive symptomatology will be proposed and carried out in the patient due to clinical needs, based on the judgment of the competent physician and as would already be the case in practice, thus completely independent of participation or non-participation in the present study. Neuroimaging data will be obtained with a Philips 3T magnetic resonance imaging MRI machine. For each patient enrolled in the study, a structural T1 sequence (3D MPRAGE) is acquired.
T1-weighted MRI images will be used to study the differences brain morphology, including the volumes of gray matter (GM) and white matter (WM) and voxel-based morphometry. In a comparison parallel between regions of interest (ROIs), regional volumes will be estimated using the automated anatomical labeling atlas (AAL) as a reference, with emphasis on the dorsolateral PFC (DL)/ventrolateral (VL), cingulate cortex, amygdala and hippocampus. Further regional analysis will allow estimation, in addition to cortical volumes and subcortical volumes, cortical thickness, cortical surface area, and the cortical gyrification of the Desikan-Killiany atlas regions. During treatment with citalopram, patients will be visited, as per standard clinical practice, every 4 weeks. At each of these follow-up visits will be administered to patients by medical specialists the Brief Psychiatric Rating Scale (BPRS) and the Hamilton Depression Rating Scale (HAM- D) to study symptomatology depression. Patients will be, instead, self-administered in Italian language the Maternal Postnatal Attachment Scale (MPAS) and the Parental Stress Index (PSI) to investigate mother-child attachment and parental stress. The time scheduled for completion of both scales will be about 40 minutes. At 12 weeks, as per practice, the MRI scan will be repeated at the S.C. Neuroradiology Department of the Foundation. The following variables will be collected as part of this study: socio-demographic variables (age, schooling, socio-economic);
570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.
This study's planned enrollment of 15 is below the median of 223 across 100 observational studies indexed under Depression, Postpartum.
Browse Depression, Postpartum studies →Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 237 studies on the registry; 81 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women, aged 18 years to 40 years of age or older, with PPD who will be enrolled by the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.
Drug: Citalopram
Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
Change From Baseline in Total White Matter (WM) Volume at Week 12
Total white matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total WM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.
Time frame: Baseline and week 12
Change From Baseline in Total Gray Matter (GM) Volume at Week 12
Total gray matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total GM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.
Time frame: Baseline and week 12
Change From Baseline in Total Brain Volume at Week 12
Total brain volume, expressed in cubic millimeters (mm³), will be calculated as the sum of total gray matter and total white matter volumes obtained from SPM12 segmentation of 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner. A single value per participant will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.
Time frame: Baseline and week 12
Change From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12
Depressive symptom severity will be assessed with the clinician-administered 21-item Hamilton Depression Rating Scale (HAM-D). Higher scores indicate more severe depression. The change from baseline (week 12 minus baseline) in total score will be reported.
Time frame: Baseline and week 12
Percentage of Participants Responding to Treatment at Week 12
Response is defined as a reduction of at least 30% in the 21-item Hamilton Depression Rating Scale (HAM-D) total score at week 12 compared with baseline. Higher HAM-D scores indicate more severe depression. The percentage of participants meeting the response criterion will be reported.
Time frame: Baseline and week 12
Number of Participants With Adverse Events Related to Citalopram
Number of participants experiencing at least one serious or non-serious adverse event judged by the medical staff to be related to citalopram, from treatment start through week 12.
Time frame: From baseline through week 12
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for Jan 2027, 41 months after the start.
Of 51 non-industry observational studies under Depression, Postpartum, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's planned 41 months is above that.
Counting every sponsor, half of 53 studies reached it within 25 months; a quarter within 6 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jan 2024 → Aug 2023, primary completion Dec 2025 → Jan 2027 and completion Apr 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →